Cencora, Inc. (NYSE:COR) CAO Sells $520,120.00 in Stock

Cencora, Inc. (NYSE:COR) CAO Lazarus Krikorian sold 2,000 shares of the business’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the transaction, the chief accounting officer now directly owns 20,154 shares of the company’s stock, valued at $5,241,249.24. The trade was a 9.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Cencora Price Performance

NYSE:COR traded down $0.69 during mid-day trading on Tuesday, reaching $260.87. 2,532,540 shares of the stock were exchanged, compared to its average volume of 1,353,283. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The business has a fifty day moving average price of $245.08 and a 200 day moving average price of $238.54. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $262.93. The firm has a market capitalization of $50.59 billion, a PE ratio of 37.11, a PEG ratio of 1.31 and a beta of 0.51.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.84%. Cencora’s dividend payout ratio is currently 31.29%.

Analyst Upgrades and Downgrades

COR has been the topic of a number of recent analyst reports. StockNews.com cut Cencora from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Wells Fargo & Company lifted their target price on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 29th. JPMorgan Chase & Co. increased their price target on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Mizuho started coverage on Cencora in a report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price target on the stock. Finally, Evercore ISI upped their price objective on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $277.90.

Institutional Investors Weigh In On Cencora

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Wood Tarver Financial Group LLC acquired a new stake in shares of Cencora during the fourth quarter worth $136,000. Siemens Fonds Invest GmbH raised its holdings in Cencora by 944.6% during the 4th quarter. Siemens Fonds Invest GmbH now owns 19,972 shares of the company’s stock worth $4,645,000 after buying an additional 18,060 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Cencora during the 4th quarter worth about $38,652,000. Azzad Asset Management Inc. ADV lifted its stake in Cencora by 34.5% during the fourth quarter. Azzad Asset Management Inc. ADV now owns 10,905 shares of the company’s stock valued at $2,450,000 after buying an additional 2,800 shares in the last quarter. Finally, Jefferies Financial Group Inc. boosted its holdings in shares of Cencora by 61.6% in the fourth quarter. Jefferies Financial Group Inc. now owns 9,375 shares of the company’s stock worth $2,106,000 after buying an additional 3,574 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.